News
The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2). AZ and Daiichi are already collaborating on antibody-drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback